drugset / Trial / NCT00357188

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

NCT00357188

Phase 1 Completed 22 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects

Timeline

Start
2006-07
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Atazanavir Other / unclassified 400 mg Oral
Comparator Efavirenz Other / unclassified 600 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral